{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T09:30:20Z","timestamp":1793611820677,"version":"4.5.0"},"reference-count":32,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Shanghai Anticancer Association","award":["SACA-AX202407"],"award-info":[{"award-number":["SACA-AX202407"]}],"id":[{"id":"https:\/\/ror.org\/031vgn537","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,9,15]]},"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1136\/bmjopen-2026-120892","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:42:21Z","timestamp":1790862141000},"page":"e120892","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct06738160","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4212-7192","authenticated-orcid":false,"given":"Jin","family":"Li","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"},{"name":"Shanghai Clinical Research Center for Radiation Oncology, Shanghai, China"},{"name":"Shanghai Key Laboratory of Radiation Oncology, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianlan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Northern Jiangsu People\u2019s Hospital, Yangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiquan","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"},{"name":"Shanghai Clinical Research Center for Radiation Oncology, Shanghai, China"},{"name":"Shanghai Key Laboratory of Radiation Oncology, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangjun","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"},{"name":"Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengfei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"},{"name":"Shanghai Clinical Research Center for Radiation Oncology, Shanghai, China"},{"name":"Shanghai Key Laboratory of Radiation Oncology, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"},{"name":"Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026110201100513000_16.10.e120892.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"2026110201100513000_16.10.e120892.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2026110201100513000_16.10.e120892.3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.5-6-463"},{"key":"2026110201100513000_16.10.e120892.4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17101674","article-title":"Cancer Cell Colonisation in the Bone Microenvironment","volume":"17","author":"Kan","year":"2016","journal-title":"Int J Mol Sci"},{"key":"2026110201100513000_16.10.e120892.5","doi-asserted-by":"crossref","DOI":"10.1038\/srep18670","article-title":"Natural History of Non-Small-Cell Lung Cancer with Bone Metastases","volume":"5","author":"Santini","year":"2015","journal-title":"Sci Rep"},{"key":"2026110201100513000_16.10.e120892.6","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-007-0051-0"},{"key":"2026110201100513000_16.10.e120892.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2013.05.002"},{"key":"2026110201100513000_16.10.e120892.8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.871675","article-title":"The Therapeutic Effect and Clinical Outcome of Immune Checkpoint Inhibitors on Bone Metastasis in Advanced Non-Small-Cell Lung Cancer","volume":"12","author":"Asano","year":"2022","journal-title":"Front Oncol"},{"key":"2026110201100513000_16.10.e120892.9","doi-asserted-by":"crossref","first-page":"12425","DOI":"10.1002\/cam4.5952","article-title":"Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis","volume":"12","author":"Asano","year":"2023","journal-title":"Cancer Med"},{"key":"2026110201100513000_16.10.e120892.10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23126832","article-title":"Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications","volume":"23","author":"Del Conte","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026110201100513000_16.10.e120892.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30072-X"},{"key":"2026110201100513000_16.10.e120892.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3310"},{"key":"2026110201100513000_16.10.e120892.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.08.002"},{"key":"2026110201100513000_16.10.e120892.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.2146"},{"key":"2026110201100513000_16.10.e120892.15","doi-asserted-by":"crossref","first-page":"9541","DOI":"10.1038\/s41467-024-53686-4","article-title":"Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib\/II study","volume":"15","author":"Xu","year":"2024","journal-title":"Nat Commun"},{"key":"2026110201100513000_16.10.e120892.16","doi-asserted-by":"crossref","first-page":"971594","DOI":"10.3389\/fonc.2022.971594","article-title":"Safety, tolerability, and pharmacokinetics\/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors","volume":"12","author":"Liang","year":"2022","journal-title":"Front Oncol"},{"key":"2026110201100513000_16.10.e120892.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.09.012"},{"key":"2026110201100513000_16.10.e120892.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0561-4"},{"key":"2026110201100513000_16.10.e120892.19","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-024-02437-2","article-title":"Pamiparib as consolidation treatment after concurrent chemoradiotherapy of limited-stage small cell lung cancer: a single-arm, open-label phase 2 trial","volume":"19","author":"Mao","year":"2024","journal-title":"Radiat Oncol"},{"key":"2026110201100513000_16.10.e120892.20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1187"},{"key":"2026110201100513000_16.10.e120892.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"2026110201100513000_16.10.e120892.22","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14933"},{"key":"2026110201100513000_16.10.e120892.23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial","volume":"8","author":"Welsh","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026110201100513000_16.10.e120892.24","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal5081","article-title":"Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils","volume":"358","author":"Engblom","year":"2017","journal-title":"Science"},{"key":"2026110201100513000_16.10.e120892.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.10.012"},{"key":"2026110201100513000_16.10.e120892.26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20040999","article-title":"The Contribution of the Immune System in Bone Metastasis Pathogenesis","volume":"20","author":"Xiang","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026110201100513000_16.10.e120892.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-010-0596-4"},{"key":"2026110201100513000_16.10.e120892.28","doi-asserted-by":"crossref","first-page":"107858","DOI":"10.1016\/j.lungcan.2024.107858","article-title":"Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases","volume":"193","author":"Asano","year":"2024","journal-title":"Lung Cancer"},{"key":"2026110201100513000_16.10.e120892.29","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.6"},{"key":"2026110201100513000_16.10.e120892.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.06.001"},{"key":"2026110201100513000_16.10.e120892.31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1790"},{"key":"2026110201100513000_16.10.e120892.32","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-120892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T09:10:14Z","timestamp":1793610614000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-120892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,1]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/bmjopen-2026-120892"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-120892","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}